DSM on Capital Markets Day.

the global life sciences and materials science stake company Royal DSM Group recently held a capital market day event in Vaalsbroek, the Netherlands, announced the company's 2015 strategy progress and objectives updates, and announced the current trading situation.
4g3 ."Three years ago, we launched the company's new strategy of "focusing on goals and making progress", setting ambitious strategic goals and visions," said Mr. Sheaberman, DSM's global chief executive and chairman. Since then, our business has undergone a major transformation, with more stable and higher-quality returns. In the process, we have implemented a wide range of profitability promotion programs. DSM is steadily moving towards the goals set in 2010 and we will continue to focus on improving profitability. "
4g3at Capital Markets Day, DSM announced the following information:
4g 3business transformation is in line with global trends, supported by the four major growth engines (high-growth economies, innovation, sustainability and mergers and acquisitions
and cooperation
); DSM's position in high-growth economies is growing rapidly, with about 40 per cent of total global sales coming from high-growth economies, and
4g3innovation and sustainability are becoming engines of future growth and profitability. Three exciting emerging business areas, including bio-based products and services, biomedicine and advanced surfaces, are creating new business opportunities, and
4g3l's strategic objectives for 2015. The new target reflects the transformation of the business portfolio and new market trends, with ebitda (EBITDA) of 14-15% and return on capital (ROCE) target 11-12%.
4g3 .In addition, DSM will focus on the next two years:
4g3to complete the strategic action of the DSM Pharmaceuticals and Polymer Intermediates business,
4g3 l integrate the acquired companies to maximize synergies and drive organic growth, and
4g3 l to improve business performance.
4g3 .During the Capital Markets Day event, DSM also elaborated on current market trends:
4g3 the sluggish macroeconomic environment in the first half of 2013 will continue, Europe' s growth will continue, growth will be slow or almost no growth, the Asian economy, although the growth rate is modest, but continued to be active, the U.S. economy has achieved a certain recovery
; However, the recovery of the animal protein market is still slow, leading to some price pressures for products such as vitamin E. In addition, sales of Omega-3 fish oil have been affected by the fact that rapid increases in retail prices have dampened consumer demand. But overall, the growth momentum of the nutrition business remains strong;
4g3 l Pharmaceuticals, the environment remains challenging, and Despite significant quarterly performance, DSM believes significant improvements will be made in the future;
4g3 performance materials business is expected to improve in 2013, although the end of the
4g3 l polymer intermediate sits, and the performance of the
4g3 l innovation center is expected to decline in the second half of 2012.
4g3 .Overall, DSM EBITDA for 2013 is expected to increase significantly from EUR 1.1 billion in 2012. This is due to strong organic growth, DSM's earnings promotion program, and the positive impact of mergers and acquisitions and a more resilient business mix. Exchange rate changes and the recent announcement by the Dutch government of the continuation of the "crisis-time tax regime" may have a negative impact on EBITDA. Overall, DSM is on track to meet its 2013 EBITDA target of 1.4 billion euros, based on current economic forecasts. However, these factors could lead to DSM's 2013 EBITDA of just under 1.35 billion euros.
4g3 .Share repurchases support existing stock option sorups
4g3the fourth quarter of 2013, DSM will launch an equity repurchase program and buy back 4-5 million shares to honor the existing management and employee stock option incentive program. The program is expected to continue into the first quarter of 2014.
4g3 .DSM - Colorful Technology, A Good Life?
4g3 .In 111, the Royal DSM Group of the Netherlands is active in the field of health, nutrition and materials, based on science and technology. DSM has expertise in life sciences and materials science, and uses its unique combination to drive economic prosperity, environmental improvement and social progress to create sustainable value for all stakeholders. DSM serves end markets such as food and health products, personal care, feed, pharmaceuticals, medical devices, automotives, coatings and paints, electrical and electronic, life protection, alternative energy and bio-based materials, creating sustainable solutions worldwide that promote nutrition, enhance and ensure product efficacy and improve product performance. DSM's 23,500 employees worldwide generate annual sales of approximately 9 billion euros. The company is listed on NYSE Euronext on nyse Euronext. For more information, please visit

.
4g3 .DSM in China
4g3DSM began trading with China as early as 1963, and in the early 1990s established its first sales representative office and first production site in China. DSM China's regional headquarters and research and development center are located in Shanghai. At present, the company has 40 branches in China, including 26 production sites, employing about 3,500 people. DSM's business in China grew steadily, with sales of $1.7 billion in 2012. For more information, please visit

.
4g3
The Royal DSM Group, a global life sciences and materials sciences specialist, recently held a capital markets day event in Vaalsbroek, the Netherlands, announcing updates on the company's 2015 strategy progress and objectives, as well as the current trading situation.
4g3 ."Three years ago, we launched the company's new strategy of "focusing on goals and making progress", setting ambitious strategic goals and visions," said Mr. Sheaberman, DSM's global chief executive and chairman. Since then, our business has undergone a major transformation, with more stable and higher-quality returns. In the process, we have implemented a wide range of profitability promotion programs. DSM is steadily moving towards the goals set in 2010 and we will continue to focus on improving profitability. "
4g3at Capital Markets Day, DSM announced the following information:
4g 3business transformation is in line with global trends, supported by the four major growth engines (high-growth economies, innovation, sustainability and mergers and acquisitions
and cooperation
); DSM's position in high-growth economies is growing rapidly, with about 40 per cent of total global sales coming from high-growth economies, and
4g3innovation and sustainability are becoming engines of future growth and profitability. Three exciting emerging business areas, including bio-based products and services, biomedicine and advanced surfaces, are creating new business opportunities, and
4g3l's strategic objectives for 2015. The new target reflects the transformation of the business portfolio and new market trends, with ebitda (EBITDA) of 14-15% and return on capital (ROCE) target 11-12%.
4g3 .　　In addition, DSM will focus on the next two years:
4g3 to complete the strategic action of the DSM Pharmaceuticals and Polymer Intermediates business,
4g3 l integrate the acquired companies to maximize synergies and drive organic growth, and
4g3 l to improve business performance.
4g3 .　　During the Capital Markets Day event, DSM also elaborated on current market trends:
4g3 the sluggish macroeconomic environment in the first half of 2013 will continue, Europe' s growth will continue, growth will be slow or almost no growth, the Asian economy, although the growth rate is modest, but continued to be active, the U.S. economy has achieved a certain recovery
; However, the recovery of the animal protein market is still slow, leading to some price pressures for products such as vitamin E. In addition, sales of Omega-3 fish oil have been affected by the fact that rapid increases in retail prices have dampened consumer demand. But overall, the growth momentum of the nutrition business remains strong;
4g3 l Pharmaceuticals, the environment remains challenging, and Despite significant quarterly performance, DSM believes significant improvements will be made in the future;
4g3 performance materials business is expected to improve in 2013, although the end of the
4g3 l polymer intermediate sits, and the performance of the
4g3 l innovation center is expected to decline in the second half of 2012.
4g3 .　　Overall, DSM EBITDA for 2013 is expected to increase significantly from EUR 1.1 billion in 2012. This is due to strong organic growth, DSM's earnings promotion program, and the positive impact of mergers and acquisitions and a more resilient business mix. Exchange rate changes and the recent announcement by the Dutch government of the continuation of the "crisis-time tax regime" may have a negative impact on EBITDA. Overall, DSM is on track to meet its 2013 EBITDA target of 1.4 billion euros, based on current economic forecasts. However, these factors could lead to DSM's 2013 EBITDA of just under 1.35 billion euros.
4g3 .　　Share repurchases support existing stock option sorups
4g3 the fourth quarter of 2013, DSM will launch an equity repurchase program and buy back 4-5 million shares to honor the existing management and employee stock option incentive program. The program is expected to continue into the first quarter of 2014.
4g3 .　　DSM - Colorful Technology, A Good Life?
4g3 .　　In 111, the Royal DSM Group of the Netherlands is active in the field of health, nutrition and materials, based on science and technology. DSM has expertise in life sciences and materials science, and uses its unique combination to drive economic prosperity, environmental improvement and social progress to create sustainable value for all stakeholders. DSM serves end markets such as food and health products, personal care, feed, pharmaceuticals, medical devices, automotives, coatings and paints, electrical and electronic, life protection, alternative energy and bio-based materials, creating sustainable solutions worldwide that promote nutrition, enhance and ensure product efficacy and improve product performance. DSM's 23,500 employees worldwide generate annual sales of approximately 9 billion euros. The company is listed on NYSE Euronext on nyse Euronext. For more information, please visit

.
4g3 .　　DSM
4g3 DSM began trading with China as early as 1963 and established its first in China in the early 1990s.